First Intracardiac Kaposiform Hemangioendothelioma in an Infant Resolved With Sirolimus: A Case Report

被引:6
|
作者
Zaidi, Syed Javed [1 ]
Shaik, Shaista [2 ]
Agrawal, Caitlin [3 ]
Cossor, Waseem [1 ]
机构
[1] Advocate Childrens Hosp, Dept Pediat Cardiol, 4440 W95th St, Oak Lawn, IL 60453 USA
[2] Advocate Lutheran Gen Hosp, Dept Pediat Intens Care, Park Ridge, IL USA
[3] Advocate Lutheran Gen Hosp, Dept Pediat Hematol Oncol, Park Ridge, IL USA
关键词
hemangioma; Kasabach-Merritt phenomenon; infant; cardiac tumor; pericardial effusion; KASABACH-MERRITT PHENOMENON; VASCULAR TUMORS; HUMAN-DISEASE; VINCRISTINE; HEMANGIOMA; THERAPY; MTOR; TICLOPIDINE; EVEROLIMUS; CHILDREN;
D O I
10.1097/MPH.0000000000001275
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Kaposiform hemangioendothelioma (KHE) is a rare and aggressive vascular tumor that can be associated with a consumptive coagulopathy and thrombocytopenia (Kasabach-Merritt phenomenon). Only one case of an intracardiac KHE has been reported which was treated with surgical excision and then expectant management. Case Presentation: We present a patient with an intracardiac KHE which presented as a large mass surrounding the atria, pulmonary veins, superior vena cava, and infiltrating the atrial septum with moderate compression of the superior vena cava and mild compression of the pulmonary veins. This tumor clinically presented as persistent tachypnea and was unresponsive to conventional therapy with vincristine and steroids but responded dramatically to Sirolimus with almost complete regression on follow-up. Conclusions: None of the current treatments for KHE, alone or in combination therapy have been found to be effective in a uniform or reproducible manner. Well designed, preferably randomized trials are required for a better understanding of the appropriate dosage and duration as well as response to treatment and a consensus of first and second line therapies.
引用
收藏
页码:536 / 540
页数:5
相关论文
共 50 条
  • [1] A case of sirolimus treatment of kaposiform hemangioendothelioma in the neck
    Kuwabara, Yuya
    Ozeki, Michio
    Hira, Kota
    Fujisaki, Hiroyuki
    Ohnishi, Hidenori
    PEDIATRICS INTERNATIONAL, 2022, 64 (01)
  • [2] Kaposiform hemangioendothelioma: A case report
    Oral, O.
    Gezer, E. Kaymaz
    VIRCHOWS ARCHIV, 2016, 469 : S331 - S332
  • [3] Kaposiform Hemangioendothelioma:a Case Report
    Leina Sun Zhongli Zhan Department of Pathology
    Chinese Journal of Clinical Oncology, 2006, (04) : 303 - 304
  • [4] SIROLIMUS FOR KAPOSIFORM HEMANGIOENDOTHELIOMA IN A NEONATE
    Cabrera, T. B.
    Speer, A. L.
    Greives, M. R.
    Goff, D. A.
    Menon, N. M.
    Reynolds, E. W.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2020, 68 (02) : 447 - 447
  • [5] Management of Refractory Mandibular Kaposiform Hemangioendothelioma with Sirolimus: A Case Report and Review of the Literature
    Rikhotso, Risimati Ephraim
    Alharbi, Abdulaziz Abdullah
    JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2021, 79 (10) : 2086.e1 - 2086.e8
  • [6] Successful Management of Pancreatic Kaposiform Hemangioendothelioma With Sirolimus Case Report and Literature Review
    Wang, Chuan
    Li, Yanan
    Xiang, Bo
    Li, Fuyu
    Chen, Siyuan
    Li, Li
    Ji, Yi
    PANCREAS, 2017, 46 (05) : E39 - E41
  • [7] Management of pancreatic kaposiform hemangioendothelioma with sirolimus in a pediatric patient: a case report and literature review
    Liang, Zijian
    Lan, Menglong
    Xu, Xiaogang
    Liu, Fei
    Tao, Boyuan
    Chen, Zhen
    Zeng, Jixiao
    TRANSLATIONAL PEDIATRICS, 2022, 11 (08) : 1422 - 1430
  • [9] Treatment of Childhood Kaposiform Hemangioendothelioma With Sirolimus
    Blatt, Julie
    Stavas, Joseph
    Moats-Staats, Billie
    Woosley, John
    Morrell, Dean S.
    PEDIATRIC BLOOD & CANCER, 2010, 55 (07) : 1396 - 1398
  • [10] Sirolimus (Rapamycin) in patients with Kaposiform hemangioendothelioma. Clinical case
    Rodriguez Z, Natalie
    Benavides J, Pablo
    REVISTA CHILENA DE PEDIATRIA-CHILE, 2013, 84 (05): : 537 - 544